Drugs / IONIS DGAT2Rx
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03334214 | Nov 2017 → Nov 2018 | fatty liver disease | Ionis Pharmaceuticals, Inc. | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IONIS-DGAT2Rx | “IONIS-DGAT2Rx is an antisense oligonucleotide inhibitor of DGAT2 that is under clinical investigation for the treatment of non-alcoholic fatty liver disease (NAFLD) and...” PMID 32553151 ↗ Jun 2020 |
| Action | Inhibit | “antisense oligonucleotide inhibitor of DGAT2” PMID 32553151 ↗ Jun 2020 |
| Modality | Antisense oligonucleotide | “IONIS-DGAT2Rx is an antisense oligonucleotide inhibitor of DGAT2” PMID 32553151 ↗ Jun 2020 |
| Route | Subcutaneous | “once weekly subcutaneous injection of 250 mg IONIS-DGAT2Rx” PMID 32553151 ↗ Jun 2020 |
| Target | DGAT2 | “antisense oligonucleotide inhibitor of DGAT2” PMID 32553151 ↗ Jun 2020 |